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Abstract   
Vitamin E is composed of two structurally similar compounds: tocopherols (TP) and 
tocotrienols (T3). Despite being overshadowed by TP over the past few decades, T3 is 
now considered to be a promising anti-cancer agent due to its potent effects against a 
wide range of cancers. A growing body of evidence suggests that in addition to its 
anti-oxidative and pro-apoptotic functions, T3 possesses a number of anti-cancer 
properties that make it superior to TP. These include the inhibition of 
epithelial-to-mesenchymal transitions, the suppression of VEGF tumor angiogenic 
pathway and the induction of anti-tumor immunity. More recently, T3, but not TP, has 
been shown to have chemosensitization and anti-cancer stem cell (CSC) effects, further 
demonstrating the potential of T3 as an effective anti-cancer therapeutic agent. With 
most of the previous clinical studies on TP producing disappointing results, research 
has now focused on testing T3 as the next generation vitamin E for chemoprevention 
and cancer treatment. This review will summarize recent developments in the 
understanding of the anti-cancer effects of T3. We will also discuss current progress in 
clinical trials involving T3 as an adjuvant to conventional cancer therapy.  
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Introduction 
Tocopherols (TP) and tocotrienols (T3) belong to the vitamin E family, each composed 
of four different isomers: alpha, beta, gamma and delta. The chemical structures of TP 
and T3 are made up of an aromatic chromanol ring and an isoprenoid chain, with T3 
containing three unsaturated phytyl side chains [1]. Both TP and T3 are well-known 
antioxidants and are potent in scavenging peroxyl radicals through their chromanol ring 
[2,3]. Whereas TP is found in the leaves and seeds of most plants, T3 is less abundant, 
present mainly in palm oil and rice bran. Both TP and T3 are absorbed into the intestine 
along with dietary fats and are secreted in chylomicrons, entering circulation via the 
lymphatic system [4]. T3 is rapidly cleared from circulating plasma, whereas TP, 
especially alpha-TP (α-TP), is preferentially secreted into plasma [5]. The half-life of α-, 
gamma- (γ-) and/or delta- (δ-) T3 in plasma ranges from two to four hours, and it is four 
to eight fold shorter than the half-life reported for α-TP [6]. Thus, among the vitamin E 
isomers, α-TP is the most common form found in human diets; it also has the highest 
bioavailability.  
Owing to its highest bioavailability, α-TP is the best characterized vitamin E isomer and 
has been examined in a large number of studies [7]. Data from early epidemiological 
studies suggest that vitamin E consumption may be associated with reduction of 
prostate cancer incidence. For example, in the Alpha-Tocopherol Beta-Carotene 
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Cancer Prevention Study, male smokers who consumed α-TP daily were found to have 
a 32% decrease in prostate cancer incidence [8]. Low intake of vitamin E was also 
associated with increased rectal cancer incidence in women[9]. Despite of these 
promising data, in two of the largest chemoprevention trials of this century, vitamin E 
(α-TP to be precise) consumption was found to have no beneficial effect in reducing 
cancer incidence [10,11]. In the Woman Health Study (WHS) trial, women who took 
α-TP every other day had a similar chance of developing lung, breast and colon cancer 
as those who took the placebo [10]. Similarly, in the Selenium, Vitamin E and Prostate 
Cancer Chemoprevention Trial (SELECT) that was completed in 2008, α-TP 
consumption, either alone or in combination with selenium, was found to have no 
significant effect in reducing prostate cancer incidence [11].  
Due to the disappointing results from these two clinical trials, as well as several recent 
in vitro studies that will be discussed in detail in this review, research has now been 
refocused on the T3 isomers. Here, we will summarize some of the recent data 
demonstrating the unique anti-cancer effects of T3. We will discuss how these distinct 
properties may make T3 a promising chemopreventive and chemotherapeutic agent. 
Finally, we will highlight the recent progress in the development and testing of 
T3-based cancer therapies.  
Tocotrienols in cancer chemoprevention 
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Although T3 has not yet been evaluated as a chemopreventive agent in large scale 
clinical trials, its chemopreventive properties have been studied extensively in a 
number of animal models.  In contrast to the effects of α-TP in animal carcinogenesis 
models (colon, prostate, mammary and lung) that often produce inconsistent results 
[12], most of the studies on T3 have demonstrated positive chemopreventive effects 
[13-18].  However, mechanistic explanations for its unique chemopreventive effect 
remain hypothetical (Figure. 1).  
a) Chemoprevention of T3 in animal tumor models 
Two early reports which compared the chemopreventive ability of TP and T3-enriched 
sources in 7,12-dimethylbenz(a)anthracene (DMBA)-induced rat mammary 
carcinoma models found that T3 treatment is associated with significantly lower 
tumor incidence, lower tumor numbers, and longer tumor latency [14,15] when 
compared to the TP treatment and control groups. In a 2-acetylaminofluorene-induced 
rat hepatocarcinogenesis model, T3 administration was associated with a reduced 
severity of hepatocarcinogenesis [16] and decelerated liver tumor formation [17,18]. 
In addition, Wada et al [19] demonstrated that oral administration of a tocotrienol-rich 
fraction (TRF) resulted in a significant reduction of tumor number per mouse in a 
spontaneous model of liver carcinogenesis. The same group also showed that this TRF 
can suppress lung tumor formation induced by 4NQO and glycerol [19]. Recently, 
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using a transgenic adenocarcinoma mouse prostate (TRAMP) mouse model, Barve et 
al [20] showed that daily supplementation with a TRF for 16 weeks resulted in a 
lower incidence of prostate tumor formation. The incidence of high-grade neoplastic 
lesions was also reduced by the same treatment, clearly indicating the 
chemopreventive effect of T3 consumption [20]. Interestingly, a previous report from 
the same group as well as a recent study [21] both demonstrated that γ-TP treatment 
can also inhibit prostate cancer development [22]. The authors suggested that T3 and 
TP work differently in suppressing prostate carcinogenesis, with TP acting mainly 
through the upregulation of detoxifying and antioxidant enzymes [22], while T3 
directly modulates cell cycle regulatory proteins and increases the expression of 
pro-apoptotic proteins [20]. Collectively, T3 appears to possess chemopreventive 
properties against different types of cancer that deserves further investigation, 
especially in clinical studies. 
b) Protective role of T3 against oxidative-stress induced DNA damage 
Oxidative stress-induced DNA damage is the primary cause of genetic mutation in 
mammalian cells. Majority of the damaged DNA are detected and repaired by the 
DNA damage checkpoint but the unrepaired damage will accumulate and eventually 
lead to cancer development. Recently, T3 has been suggested to play a protective role 
against oxidative stress-induced DNA damage, which may contribute to its  
 at Queensland University of Technology on November 22, 2011
http://carcin.oxfordjournals.org/
D
ow
nloaded from
 
chemopreventive function. Convincing evidence came from a recent animal study by 
Budin et al [23], which demonstrated that consumption of TRF significantly reduced 
oxidative DNA damage. The anti-oxidative effect of T3 appears to play a major role 
as the decrease in DNA damage was associated with a reduction in the lipid 
peroxidation by-products (malondealdehyde and 4-hydroxynonenal). Similar results 
was obtained by the study of Taridi et al [24], which reported a decrease in DNA 
damage and an improvement in cognitive function in rats that fed with TRF. These 
findings were consistent with that reported in a randomized clinical trial which 
demonstrated that consumption of a TRF not only reduced the level of the oxidative 
stress marker 8-hydroxy-2-deoxyguanosine in urine sample, but also significantly 
suppressed the level of DNA damage in the same human subjects [25]. 
Notably, the protective effect of T3 is not specific for oxidative stress-induced DNA 
damage. Using gamma and delta-T3 respectively, two recent studies reported the 
protection of hematopoietic progenitor cells from gamma-irradiation induced DNA 
damage [26,27]. The fact that TP, which has similar anti-oxidative effect as T3, failed 
to achieve the same radio-protective function suggested that T3 may induce additional 
protective mechanisms [28]. This is supported by the findings that T3, but not TP, 
regulates the expression of a number of DNA damage response genes [28]. Whether 
these genes are important for the protective effect of T3 against DNA damage remains 
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to be further elucidated.  
c) Modulation of the immune response by T3 
Immune surveillance is believed to function as the primary defense against cancer by 
detecting and destroying tumor cells. Therefore, suppression of the host immune 
response or loss of tumor immunity has been suggested to promote tumor 
development. Interestingly, two recent studies demonstrated that T3 supplementation 
has an immune promoting effect. A study by Ren et al [7], in which young or old mice 
were fed with either T3 plus TP or TP alone revealed that lymphocyte proliferation, 
which was found to be decreased in older mice, was significantly induced by T3 when 
compared to the control group. This was further confirmed by treating the isolated 
mouse lymphocytes from old mice with T3 in vitro, suggesting that T3 may have 
beneficial effects against aging-associated impairment of the immune system. 
Consistent with these observations, a recently completed clinical trial also reported 
that oral consumption of T3 has an immunostimulatory effect [29]. This study 
revealed that in healthy females who consumed 400 mg of a tocotrienol-rich fraction 
(TRF) daily for two months, antibody production after immunization with tetanus 
toxoid (TT) was significantly upregulated when compared to the placebo group, 
suggesting that T3 treatment enhanced the immune response to TT vaccination. 
However, in a separate study by the same research group, neither TRF nor TP 
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supplementation were found to affect the immune parameters of healthy individuals 
[30], although the use of lower T3 concentrations in this study may account for these 
differences. 
More importantly, apart from enhancing the immune response to the TT vaccine, T3 
was also found to promote tumor-induced immunity in 4T1 murine mammary 
carcinoma model. In mice injected with dendritic cells (DCs) pulsed with 4T1 cancer 
cell lysate, daily oral supplementation of TRF was found to significantly suppress 
tumor onset after inoculation with 4T1 cells [31]. This effect was associated with an 
enhanced production of the immune stimulatory cytokines IFN-γ and IL-12 by DCs 
and splenocytes, suggesting that TRF induces cytokine release and promotes a tumor 
cell-mediated immune response [31].  
d) Targeting cancer stem cells by T3 
Cancer stem cells (CSCs), also known as tumor initiating cells (TICs), are 
subpopulations of cells within cancers with self renewal and multi-lineage potential 
and are believed to be responsible for the development of human tumors. CSCs were 
first identified in leukemia patients and later on in a wide-range of solid tumors. They 
are characterized by their ability to self-renew, form spheroid structures in vitro, and 
differentiating to form the bulk of the tumor in vivo. It is believed that early 
elimination of CSCs may confer cancer chemoprevention, although an anti-CSC 
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specific agent is yet to be developed. Interestingly, a recent study by our laboratory 
reported that the gamma form of T3 (γ-T3) has potent anti-CSC properties. We found 
that treatment of prostate cancer cell lines with γ-T3 significantly inhibited the 
spheroid formation ability of the cells, which was associated with the downregulation 
of CSC marker expression [32]. Consistent with this, oral administration of γ-T3 was 
found to suppress tumor formation in more than 70% of mice subcutaneously injected 
with prostate cancer cells [32], further validating the anti-CSC effect of γ-T3. 
Intriguingly, γ-T3 treatment in prostate cancer cells was found to downregulate the 
protein levels of Id-1 and beta-catenin [32], two well-documented stem cell 
maintenance proteins which promote stem cell survival and self-renewal ability 
[33,34]. However, the same treatment failed to affect the mRNA levels of either genes 
(unpublished data), suggesting that γ-T3 may regulate the protein levels of Id-1 and 
beta-catenin through a post-transcriptional mechanism. Thus, while these findings 
clearly demonstrate the potential anti-CSC properties of γ-T3, the underlying 
mechanism is still far from clear. 
 
Tocotrienols as an anti-cancer agent 
a) Selective cancer cell-killing effect 
In addition to its chemopreventive effect, ample evidence suggests that T3 may also 
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be an effective cancer therapeutic agent. One intriguing finding, which was 
demonstrated consistently by us and others is its selective killing effect against cancer 
cells. In our recent studies, T3 was found to induce apoptosis in prostate and breast 
cancer cells, but not in the non-malignant breast and prostate epithelial cells [35,36], 
suggesting that it has selective cancer cell-killing properties. In addition, in both 
studies, the hormone independent cell lines were found to be more sensitive to T3 
than the hormone dependent lines, which highlight the potential of T3 in targeting 
breast and prostate tumors at hormone refractory stage. Similar findings were 
reinforced by Srivastava et al [37], wherein TRF was found to inhibit the growth and 
viability of prostate cancer cells, yet the same treatment was unable to induce 
significant cell death in non-malignant prostate epithelial cells. This selectively may 
in fact be due to the induction of interleukin-24 (IL24) [38], a cytokine known to 
specifically induce apoptosis of cancer cells but not of the normal cells. A higher 
uptake of T3 by cancer cells may also account for the observed cancer cell specific 
killing effect, since examination of T3 distribution in vivo revealed that T3 tends to 
accumulate at a much higher concentration in tumor tissues when compared to other 
vital organs [39]. Meanwhile, despite its low bioavailability in comparison to TP, T3 
has a >16 folds higher uptake rate than TP, which may explain the ineffectiveness of 
TP as anti-cancer agent in our and other studies [32,40]. 
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b) Therapeutic inhibition of cell migration and invasion  
Liu et al [41] demonstrated that in gastric adenocarcinoma SGC-7901 cells, γ-T3 
treatment leads to inhibition of cell migration and matrigel invasion through 
downregulation of transcription of matrix metalloproteinases (MMP-2 and MMP-9), 
as well as upregulation of tissue inhibitors of metalloproteinase-1 (TIMP-1 and 
TIMP-2). Similarly, in two of our recent studies, γ-T3 was found to significantly 
inhibit the invasive ability of melanoma and prostate cancer cells [35,42]. In addition, 
in both studies, γ-T3 was found to upregulate expression of epithelial markers such as 
E-cadherin and gamma-catenin, while at the same time downregulate the level of 
mesenchymal markers like vimentin and alpha-smooth muscle actin [35,42]. These 
observations indicated that γ-T3 treatment inhibits cancer cell invasion through 
reversal of the epithelial to mesenchymal transition (EMT), a major mechanism 
associated with cancer metastasis and disease recurrence. It is also conceivable that 
the reversal of EMT by T3 may in-part contribute to the anti-cancer stem cell (CSC) 
properties of T3 discussed above because of the well documented link between EMT 
and CSC (REF) 
c) Therapeutic inhibition of angiogenesis 
The first study that demonstrated the anti-angiogenic properties of T3 was performed 
by Inokuchi et al [43], which revealed an inhibitory effect of T3 on proliferation and 
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tube formation of bovine aortic endothelial cells. Similar results were reported 
recently by Shibata et al., showing that the delta form of T3 (δ-T3) could completely 
abolish proliferation, migration and tube formation of human umbilical vein 
endothelial cells, whereas a similar dose of α-T3 had minimal effects [44]. The VEGF 
signaling pathway appears to be the major target of T3 because expression of both 
VEGF and VEGF receptor (VEGFR) have been reported to be downregulated by T3 
treatment [45]. In gastric cancer cells, γ-T3 treatment was found to modulate the 
paracrine secretion of VEGF induced by cobalt (II) chloride via the ERK signaling 
pathway [45]. Meanwhile, TRF supplementation was found to significantly reduce 
serum VEGF levels in BALB/c mice [46]. On the other hand, T3 treatment was also 
shown to downregulate VEGFR expression in endothelial cells [47]. The concomitant 
decrease in both the ligand and receptor of the VEGF signaling pathway may account 
for the severe inhibition of inflammation- or tumor-associated angiogenesis by T3 as 
reported in several recent studies [46,48,49].  
 
Tocotrienols as adjuvant cancer therapy 
Adjuvant therapies such as radiation or chemotherapeutic drugs are the treatments that 
are given in addition to surgery to suppress tumor relapse through elimination of any 
remaining cancer cells. These adjuvant therapies are designed to kill actively 
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proliferating cancer cells, but are often ineffective once the tumor metastasized. 
Furthermore, their effectiveness is often further hampered by the associated side 
effects and the development of treatment resistance. Recent studies [35,41-46,48,49] 
of T3 have provided some encouraging data demonstrating that it can, on one hand, 
inhibit tumor invasion and angiogenesis and, on the other hand, it can sensitize cancer 
cells to chemotherapy, suggesting that it can either be used alone or with additional 
chemotherapeutic agents as an effective adjuvant (Figure 2). 
c) Dual effects of T3 as radioprotector for normal cells and 
radiosensitiser for cancer cells 
Radiation therapy is one of the most widely used adjuvant anti-cancer therapies, 
which is often associated with adverse effects, with the hematopoietic system being 
the most vulnerable tissue to the treatment. Four recent reports have revealed the 
potential radioprotective nature of T3, particularly the gamma and delta isoforms. Li 
et al [27]. demonstrated that a single injection of δ-T3 protected 100% of CD2F1 mice 
from total-body, γ-irradiation-induced death (8.75 Gy) 30 days post-irradiation 
compared to an 18% survival rate in the vehicle-alone injected group [27]. 
Interestingly, δ-T3 increased cell survival rates, the regeneration of hematopoietic 
microfoci and Lin-Sca1+c-kit+ stem and progenitor cells in irradiated mouse bone 
marrow [27], suggesting that δ-T3 can promote hematopoiesis. The authors also 
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demonstrated that δ-T3 protected human hematopoietic CD34+ cells from 
radiation–induced damage in vitro through the activation of Erk/mTOR signaling [45]. 
On the other hand, Kulkarni et al. reported that γ-T3-treated mice exhibited a 90% 
recovery of Lin-c-kit+ hematopoietic stem cells seven days after total-body irradiation, 
while the vehicle-treated group remained depleted [26]. Other studies have 
demonstrated that γ-T3 can accelerate the recovery of total white blood cells [50], 
ameliorate intestinal radiation injury, and reduce vascular oxidative stress [51]. 
Intriguingly, T3 appears to protect hematopoietic stem cells, while at the same time 
sensitize tumor cells towards irradiation-induced cell death. Kumar and colleagues 
studied the effects of γ-T3 on mice with prostate cancer xenografts after irradiation 
and found that subcutaneous injections of γ-T3 24 hours prior to irradiation at the 
tumor site (5 Gy/min for a final dose of 12 Gy) resulted in a nearly 40% reduction of 
tumor size when compared to the vehicle-treated group [52]. With a growing body of 
research suggests that CSCs are inherently resistant to radiation [53-56], it is 
conceivable that the anti-CSC properties of T3 may contribute to the radiosensitizing 
effect observed in their study. However, owing to the differences in radiation doses 
and exposure areas between the study by Kumar et al [52] and by Kulkarni et al [26], 
it remains unclear if the dual effects of γ-T3 occurred simultaneously. Thus, further 
investigation is necessary to understand the role of T3 in radiation therapy of cancer.  
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d) T3 as a potent chemosensitizer 
T3 has been shown to sensitize cancer cells to different chemotherapeutic drugs. 
Reports from our laboratory suggested that in the presence of γ-T3, both melanoma 
and prostate cancer cells became highly sensitive to docetaxel-induced apoptosis, 
suggesting that γ-T3 sensitized these cells to docetaxel [35,42]. Similarly, 
Kunnumakkara et al [57] demonstrated that γ-T3 is capable of sensitizing pancreatic 
cancer to gemcitabine both in vitro and in vivo. In particular, oral administration of 
γ-T3 together with gemcitabine treatment was found to further reduce orthotopic 
pancreatic tumor volume when compared to the groups treated with either agent alone 
[57]. Recently, using both breast and pancreatic tumor xenograft models, we have 
confirmed the chemosensitization effects of γ-T3. In mice implanted with breast 
cancer cells, docetaxel plus γ-T3 treatment was found to achieve much significant 
tumor suppressive effect than either agent alone (Figure 3, Al-Ejeh F. et al, 
unpublished data). Similarly, γ-T3 treatment was also found to sensitize pancreatic 
tumor to gemcitabine treatment (Figure 3, Al-Ejeh F. et al, unpublished data), further 
validating the chemosensitizing effect of T3 on cancer cells.  
In addition to classical chemotherapeutic drugs, T3 also showed chemosensitizing 
effects to long list of targeted cancer therapeutics. A combination of γ-T3 with 
atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
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reductase, and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, acted synergistically 
to induce G0/G1 phase cell cycle arrest and apoptosis of HT29 and HCT116 colon 
cancer cells [58]. In addition, γ-T3 was also reported to sensitize cancer cells to other 
targeted cancer therapeutics such as the erlotinib (EGFR inhibitor), gefitinib (EGFR 
inhibitor), bortezomib (a proteasomal inhibitor), thalidomide (a TNF inhibitor), tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) [59-62] both in vitro and in 
vivo. 
Signaling Mechanisms underlying the anti-cancer effect of T3 
a.) NF-kappaB 
The anti-cancer effect of T3 has been linked with the inhibition of NF-kappa B 
signaling pathway (Figure 2). NF-kappa B is a key regulator in cell survival which 
regulates expression of a series of anti-apoptotic proteins and is frequently 
upregulated in cancer cells. Previously, T3 but not TP, has been shown to inhibit 
TNF-α-induced NF-Kappa B activation in pancreatic cancer cells, leading to 
subsequent downregulation of the NF-kappaB-downstream targets that are associated 
with survival (IAP1, IAP2, Bcl-xL, Bcl-2, cFLIP, XIAP, Bfl-1/A1, TRAF1, and 
survivin), proliferation (cyclin D1, COX2, and c-Myc), invasion (matrix 
metalloproteinase-9 and ICAM-1) and angiogenesis (vascular endothelial growth 
factor receptor (VEGF)) [63]. This inhibitory effect of T3 is not restricted to 
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pancreatic cancer cells, as similar observation have been reported in skin [42] and 
prostate cancer cells [35], and also in normal monocytic cells [64]. T3 appears to 
inhibit NF-Kappa B pathway by stabilizing the NF-Kappa B inhibitor IkappaB-α and 
suppressing the nuclear translocation of the NF-Kappa B p65 subunit [63]. 
Interestingly, earlier studies reported that T3 also downregulates TGFβ2 [65], which 
functions as an upstream regulator of the NK-Kappa B pathway. Meanwhile, the 
inhibitory effect of T3 was reversed by addition of mevalonate, suggesting that T3 
inhibit NF-Kappa B through a HMG-CoA reductase dependent mechanism. However, 
unlike Statin, which functions as HMGCOR inhibitor, T3 treatment was found to 
downregulate the expression of HMGCOR protein.  
b.) PI3/AKT 
The PI3/AKT signaling pathway plays an important role in the survival, proliferation 
and invasion of the cancer cells and is aberrantly activated in a wide range of cancers. 
As demonstrated by Shah et al, in mouse mammary tumor cells that treated with γ-T3, 
a drastic reduction in the phosphorylation of PDK-1 and AKT was observed [66], 
indicating a decrease in PI3/AKT activities. This inhibition was associated with 
suppression of the anti-apoptotic protein FLIP and subsequent activation of caspase-8. 
More recently, both γ- and δ-T3 were found to downregulate the expression of 
Her2/ErbB2, an upstream activator of the PI3/AKT pathway, and as a result inhibited 
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the proliferation of pancreatic cancer cells [67]. Considering the important role of the 
PI3/AKT pathway in CSC renewal and survival, the potent inhibitory effect of T3 on 
this pathway may also account for its recently revealed anti-CSC effect (Figure 2). 
 
Current progress in the clinical development of T3-based 
cancer therapy 
The accumulating evidence supporting the use of T3 as an adjuvant therapy has 
prompted researchers to study its effect in a clinical setting. A double-blind, 
placebo-controlled pilot trial that recently completed tested the effectiveness of 
adjuvant tocotrienol therapy in combination with tamoxifen in women with early 
breast cancer [68]. Two hundred forty women with estrogen receptor-positive breast 
cancer were assigned to the intervention group (TRF plus tamoxifen) or the control 
group (placebo plus tamoxifen) [68]. Examination of the 5-year breast cancer-specific 
survival and 5-year disease-free survival revealed that survival rates were only 
slightly higher in women from the intervention group when compared to the control 
group, and the difference was not statistically significant [68]. These data suggested 
that TRF might not be an effective adjuvant therapy for breast cancer patients 
undergoing tamoxifen treatment. Considering that TRF still contains TP, which may 
interfere with the absorption and the anti-cancer effect of T3, additional trials are 
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necessary to determine if pure T3 isomer can achieve better results compared to TRF.  
Meanwhile, since different T3 isomers have different elimination half-life (4.3 hr vs 
2.2 hr for δ-T3 and γ-T3 respectively) [69], separate pilot clinical trials testing each of 
these isomers will be essential for determining the toxicity profile and effective 
dosage. Recently, a phase I clinical trial was initiated to study the effect of δ-T3 
supplementation on patients with resectable pancreatic cancer, which is expected to be 
completed in July 2013 [70]. This trial is the first to test the pharmacokinetic and 
toxicology of a single T3 isomer on human subjects. Recent release of the preliminary 
data from this trial revealed that a dosage of up to 800mg per day was well tolerated 
by the pancreatic cancer patients, with further escalation to 3200mg/day being 
planned [71]. Completion of this trial will thus be the first step in determining the 
safety and toxicology profile of a single T3 isomer and providing the reference dosage 
for future phase II trial.  
There is also an increasing interest in improving the anti-cancer effect of T3 by either 
enhancing the delivery of T3 or by direct modification of its chemical structure. Ali et 
al [72] has recently described the use of the nano-lipid carrier to efficiently deliver 
simvastatin and TRF into mammary cancer cells and revealed the existence of a 
synergistic anti-cancer activity. In addition, entrapping T3 into a transferrin-bearing 
multilamellar vesicles was also shown to enhance the anti-tumor effect of T3 by up to 
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70 folds [73]. On the other hand, two recent studies also described the design and 
synthesis of the redox-silent T3 analogues which led to an improved inhibitory effect 
on the proliferation and invasion of breast cancer cells when compared to the natural 
form of T3 [74,75]. Overall, these studies have yielded promising data which may 
benefit the future development of T3 based anti-cancer therapy.  
Conclusion 
T3, especially the gamma and delta isoforms, exhibits superior anticancer effects in 
comparison to TP, which include anti-inflammation, anti-invasion, anti-angiogenesis, 
chemosensitization (Figure 2) and radiosensitization. Recent efforts also suggest that 
T3 has potential anti-CSC properties, providing new hope for the elimination of 
chemoresistant residual tumor cells, which have recently been suggested to be 
responsible tumor recurrence and relapse after therapy. Growing interest in T3 will 
doubtlessly increase our mechanistic understanding of its unique anti-cancer 
properties, such as the targeting of CSCs or reversal of EMT. With the promising 
results observed in a number of recent pre-clinical studies, research focus should now 
be put on the design of additional clinical trials to test the anti-cancer effect of T3 
(particularly the pure single isomer). Specifically, the potent effect of gamma-T3 on 
the hormone refractory breast and prostate cancer cells warrants further investigation 
of its therapeutic potential on patients with disease relapse after hormone ablation 
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therapy. The chemosensitizing effect of T3 on systemic chemotherapeutic drugs such 
as docetaxel and gemcitabine should also be tested in clinical setting, as that may 
yield considerable improvements in the management of advanced disease by 
overcoming therapeutic resistance.  
 
Figure legends 
Figure 1: Chemoprevention by tocotrienol. DNA damage induced by oxidative stress 
or radiation drives tumor development by inducing genetic mutation, with the cancer 
stem cells being the tumor initiating population. 1. Tocotrienol inhibits tumor 
development possibly through blocking oxidative stress or radiation induced DNA 
damage. 2. It also suppresses cancer stem cells self-renewal and tumorigencity through 
inactivation of the PI3/AKT/β-Catenin pathway. 3. By promoting dendritic cell 
mediated tumor immunity, tocotrienol may facilitate the elimination of tumor cells at 
the early stage of tumor initiation and achieve chemopreventive effect. 
Figure 2: Anti-cancer properties of Tocotrienol are associated with targeting of 
multiple signaling pathways. 1. Tocotrienol inhibits VEGF-dependent tumor 
angiogenesis through downregulating the expression of both VEGF and VEGF-R. 2. It 
also inactivates the PI3/AKT signaling pathway by downregulating HER2/ErbB2 
expression, which may associate with its suppressive effect on epithelial to 
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mesenchymal transition (EMT). 3. Tocotrienol inhibits cancer cell survival through 
suppression of NK-Kappa B pathway. Downregulation of the expression of HMG-CoA 
reductase appears to play an important role in this process.  
Figure 3: Efficacy of γ-T3 treatment in combination with chemotherapy in breast 
and pancreatic cancer xenograft models. Female balb/c nude mice (6 weeks of age) 
were injected with human breast cancer cells (MDA-MB-231) in the mammary fatpad 
(A) or human pancreatic cancer cells (PANC-1) subcutaneously (C). The largest 
tumor diameter (a) and the smallest tumor diameter (b) were measured using callipers 
and tumor volume was calculated as per the equation: b2 x a/2. In (A) Groups of 5 
mice each were left untreated (control) or treated with a single intraperitoneal  dose 
of 2mg/kg of docetaxel on day 0 (chemo), five intraperitoneal doses of 50mg/kg γ-T3 
(in sunflower oil) administered daily on days 1, 2, 3, 4 and 5 (γ-T3) or the 
combination of docetaxel (day 0) and γ-T3 (days 1-5). In (C) Groups of 5 mice each 
were left untreated (control) or treated with intravenous doses of 50mg/kg 
gemcitabine on days 1, 4, 7 and 10 (chemo), five intraperitoneal doses of 50mg/kg 
γ-T3 (in sunflower oil) administered daily on days 1, 2, 3, 4 and 5 (γ-T3) or the 
combination of gemcitabine (days 1, 4, 7 and 10) and γ-T3 (days 1-5). Tumor volume 
was measured on the specified days after treatments and were fitted to exponential 
growth curves using GraphPad Prism to generate the growth rates (k, day-1) for the 
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MDA-MB-231 (B) and PANC-1 (D) xenografts. 
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